Cytokinetics (CYTK) Misses Q1 EPS by 11c
Tweet
Share
E-mailGet Alerts CYTK Hot Sheet
Price: $76.15 +4.72%
EPS Growth %: +43.1%
Financial Fact:
Research and development revenues from related parties: 5.57M
Today's EPS Names:
VIVO, BIOX, PMCB, More
EPS Growth %: +43.1%
Financial Fact:
Research and development revenues from related parties: 5.57M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Cytokinetics (NASDAQ: CYTK) reported Q1 EPS of ($0.23), $0.11 worse than the analyst estimate of ($0.12). Revenue for the quarter came in at $4.4 million versus the consensus estimate of $10.1 million.
For earnings history and earnings-related data on Cytokinetics (CYTK) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Activist investor presses Xerox to review financial services arm - Bloomberg
- After an 18% summer selloff in chip stocks, Citi asks what comes next
- Citi turns more bullish on trucking stocks
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
